Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
Why the Earnings Surprise Streak Could Continue for Halozyme Therapeutics (HALO)
01:45pm, Thursday, 28'th Oct 2021
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
SA Interview: Investing In The Pharmaceutical Industry With Small Pharma Analyst
07:30am, Saturday, 16'th Oct 2021
Small Pharma Analyst is a veteran of the pharma industry and specializes in the analysis of small pharma companies. The opportunity in small-caps, leveraging their industry experience to gain an edge
Halozyme Therapeutics: Low Risk Buy And Hold
01:17pm, Friday, 01'st Oct 2021
Low risk biotech with steadily increasing revenue and earnings from ENHANZE drug delivery.
Halozyme to Participate in the 2021 Cantor Virtual Global Healthcare Conference
04:05pm, Wednesday, 15'th Sep 2021
SAN DIEGO, Sept. 15, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Elaine Sun, senior vice president and chief financial officer, will present at the 2021 Canto
Halozyme Therapeutics (HALO) Up 4.2% Since Last Earnings Report: Can It Continue?
01:16pm, Wednesday, 08'th Sep 2021
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Halozyme to Present at Wells Fargo 2021 Virtual Healthcare Conference
09:00am, Thursday, 26'th Aug 2021
SAN DIEGO, Aug. 26, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will present at the Wells Fargo 2021
Halozyme (HALO) Beats on Q2 Earnings, Raises 2021 Guidance
10:53am, Tuesday, 10'th Aug 2021
Halozyme (HALO) second-quarter earnings and sales beat estimates. The company raises 2021 guidance.
Halozyme Stock Gains As Q2 Earnings Top Estimates On Higher Milestone, Royalty; Lifts FY21 Guidance
06:51am, Tuesday, 10'th Aug 2021
Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q2 revenue of $136.5 million compared to $55.2 million a year ago, beating the consensus of $103.16 million. The increase was primarily driven by
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q2 2021 Results - Earnings Call Transcript
08:47pm, Monday, 09'th Aug 2021
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q2 2021 Results - Earnings Call Transcript
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates
07:13pm, Monday, 09'th Aug 2021
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 53.49% and 30.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics: Q2 Earnings Insights
05:30pm, Monday, 09'th Aug 2021
Shares of Halozyme Therapeutics (NASDAQ:HALO) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 247.37% over the past year to $0.66, whic
5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates
11:30am, Friday, 06'th Aug 2021
Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.
Halozyme to Participate in Canaccord Genuity 41st Annual Growth Conference
08:00am, Friday, 30'th Jul 2021
SAN DIEGO, July 30, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Elaine Sun, senior vice president and chief financial officer, will virtually represent the com
SAN DIEGO, July 12, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. (Janssen) received U.S. Food and Drug Administration (FDA) approval of DA
Halozyme (HALO) Inks Collaboration Deal With Glaxo's HIV Unit
10:32am, Wednesday, 23'rd Jun 2021
Halozyme (HALO) and Glaxo's HIV company, ViiV Healthcare sign a collaboration agreement, which gives the latter exclusive right to Halozyme's ENHANZE technology to develop therapies targeting HIV
